Logo

Tempus Reports Initiation of an Open-Label P-II Study in Collaboration with GSK to Evaluate Zejula (niraparib) to Treat Advanced or Metastatic Solid Tumors

Share this

Tempus Reports Initiation of an Open-Label P-II Study in Collaboration with GSK to Evaluate Zejula (niraparib) to Treat Advanced or Metastatic Solid Tumors

Shots:

  • The study is sponsored by Tempus, entitled “Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors” (the PAVO study), and opened for enrollment on Jan 07, 2022
  • The PAVO study will enroll solid tumor patients with germline or somatic PALB2 mutations. Tempus is utilizing its TIME Trial Program to support rapid patient identification, site activation, and clinical trial enrollment
  • Zejula is a PARP inhibitor that was approved by the US FDA in 2017 for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

Ref: Tempus | Image: GSK

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions